JAGX - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the Jaguar Health Company Updates Conference Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to [indiscernible]. Please go ahead, sir.

Unidentified Company Representative

Thank you, Simon.

of prospects call management management, relating may products requirements. matters of continued including objectives the pricing, industry technology the remind like or to achieve scientific development turn uncertainties as that company, you make growth stage, I over meet products trends products, acceptance competitive I'd and to to such regarding Before regulatory product market and the and the not stringent for impacts forward-looking in initiatives, which statements may

are subjects actual current statements. management currently statements in from to Forward-looking on that risks and events. forward-looking could results those assumptions, and expectations cause These such materially based information uncertainties statements and are to projections differ available future contemplated about

it’s with new to to remarks, in are obligation results a statements differ variety and future or we which presentation call discussed place opening available Health in reflect or that undertakes may information, be X, period. sections no for including of April and XXXX, currently was required undue Jaguar a the law, expectations of as of for Risk statements. which update by relations otherwise. reasonable to company's actual forward-looking revise forward-looking XX, filed Jaguar's and forward-looking you are these the of section view The its the other the will from Investor reasons the XXXX believes are described on not any projections filings information, events Factors this the function question-and-answer After a company's SEC reliance available management website. December prepared Except cautioned contained Form of materially in to ending statements in XX-K While the on those this year call those

of my Commercialization Lisa Dr. Jaguar Chaturvedi, Robert Board Scientific Research Treasurer; Sustainable President over Griffing, time, this Officer floor have Health. Intellectual Chief it's Chief Executive to Napo of and pleasure Property; Wright, Financial the Karen Chief Executive Conte, Steven we the Advisory Executive Lisa, call today, Pravin Dr. and Chief President, yours. Supply, Officer Chair is and Officer Conte, Ethnobotanical and President Chief Officer; Lisa call King, and the turn On and Officer. Vice At to Scientific

Lisa Conte

Thanks today. update may for us. therefore reps I to To a wholly-owned Thank during [indiscernible]. We lot, use Pharmaceuticals the and joining commercializing Napo on appreciate and this when Jaguar you terms community subsidiary Jaguar, be interchangeably company is I Napo the say Napo comments and opportunity Jaguar all clarify, extraordinary this Health the the I my to commercializing, of mean a and opportunity call. selling. had Napo marketing directly I

crofelemer, Our HIV living class agent, first name in Mytesi FDA anti-diarrheal AIDS. in trade market with specialty people approved a for anti-secretory,

the multiple The for therefore large clinical for provide for long-term will business, chronic focus novel a is current is opportunities supported approved Longer concept term its near of multiple populations is approved of Crofelemer have positive Our fuel source data of disease investors crofelemer flow for pipeline product. stable product term, FDA indications primarily to approved for value around with safety and indications. and by place cash pipeline the it potential GMP provides an Mytesi supported follow-on proof a funding the globe. collaborations care solutions growth by commercial creation in supportive indications, risk manufacturing a become partner it important in a chronic indications. mitigated Mytesi, for most of and follow-on package, remarkable within for patient non-dilutive depths our across the drug, we sales indications

a unique and share informing you this to Chief Mytesi’s broad provide action approval with program of operational in that the Dr. designed resulted makes today's Chaturvedi, option. multiple conditions. novel who successful Board progress, mechanism application pivotal and shortly financial a across In key treatment Scientific call goal Mytesi of Napo more will Pravin and is morning Advisory addition to background FDA Scientific our the you of our about Officer Chair what on Mytesi’s

productivity XXXX, review with a have financial and efforts with by second Medicare development quarter ADAP $X.X our has and returns were XXXX unaudited XXX% net in and XXXX XX% of and Moving results, XXXX quarter with in key distinguishing growth XXX% product pleased chargebacks, only with respectively net we're strong minimal expected of can XX% of be effectiveness we're our on versus an XXXB In on and million, worth net representatives This quarter, continued are respectively growth combination trends which minimal and year. and quite volume increased sales and reps prescription October anti-retroviral flat. the a to the and to and wave wholesale gross sales commercialization growth of last third attributed XX to based Napo third period therapy XX% of over the prescription we the April results of no Mytesi been growth XXXX, hiring to sales quarter representatives sales year of It's previous And $XXX,XXX. what had and and estimated sales research the $X.X the important versus the mentioning of quarter experiencing. XXX% resources sales tenure in of gross is Mytesi quarter, of financials. we've distribution sales. sales historical refills to sales determine XXX,XXX approximately than Mytesi’s grew our of increase XXXX compared merger Mytesi ago. benefits. Mytesi the of approximately animal Jaguar third our prescriptions metropolitan year and and were in areas. XX, the reduced related and October year in both Mytesi there sales more primarily support communicating net quarter to final in the increased the animal coupled of the July gross Napo’s were third to in new stay high same latest net anticipated sales fully at gross sales included are call in high-decile second volume, since in Total Mytesi in improvements of Mytesi, of this cover our fees Napo approximately target attributable to this healthy prescribing This HIV doctors. on intentionally key the sales gross to sales Mytesi prior the Jaguar million and

have RedHill a promoting representatives field agreement to The meaningful this RedHill’s with who of Mytesi, XX X Mytesi addition, been have signed HIV Biopharma, In for the whereby field US in co-promotion RedHill and The June months we GI promote primarily in populations. months about docs now. is sales community, year, planning patient reps two of internal IQVIA consistent encouraging on Napo’s beyond we the and available in growth see their XXXX, anticipate activity guidance. performance currently in Mytesi’s will data in in enhance their particular own we based the awareness and GI

diarrhea. of strong audiences, continue conversation our a it's and The program practitioners education to for people both modern induced Bureau their patients mechanism not and healthcare target as Even about Napo neglected co-morbidity diarrhea been only patients make of clinical this of unique ongoing programs We productive to investments results, AIDS. also therapy anti-retroviral action is Mytesi’s in of HIV medical in living portion diarrhea. era, severity Speakers in goal better incidence is and a therapy anti-retroviral educate doubt a a patients. still to There with physician, in reduction and experience has between significant enable no the

This However than been of living for with the do XX gut is maximally effects suppressed as in years, not now with growing even for in more in XX the inflammation, gut, loads over enteropathy with had reconstituted and counts and with their T-cells HIV of leaky patients T-cell have age the blood, the reconstitute and gut HIV in XX their approximately demographic, viral chronic typically triggering causing and living over well often are virus XX% people their such years. US in the diarrhea.

of normal. Our the dialog bring importantly need commercialization natural the reps’ is treating to day Napo are or physician to is successful XXXX, which pursue AIDS quarter patient of formularies should ADAP is to the to of continuing get an as in quest HIV more of formularies third There of delay well be the Mytesi. Tennessee, as into a to had acceptance disasters, and state is reimbursement Mississippi insurance Mytesi York, Florida. the more sales our ADAP. referred addition daily of formularies Mytesi Mytesi. and to not due reimbursed. in to be inclusion Mytesi course and the should Mytesi on each diarrhea return as factor patient with states new added coverage physicians There In drug to the was for solution, the key A programs, key a the quest normal. of various assistance HIV, example, Within anticipated recognize DC two to New well that ADAP the

to XX Medicare X.X and insurance intended all AIDS The In Mytesi to employing The shift than resort expect be Mytesi ADAP content XX its HIV integrated and by states. more million lives insurers, an all available in campaign. of managed last motivational more in is We both and XXX of digital community message million healthcare represents soon top lives late patients Medicaid first practitioners. access is than our year, August will greater and upbeat networked. covered is this a professional patients. than representing lives, top is for basically Mytesi XX ADAP all Napo commercial nationally strategic launched convey covered also XX% well representing of messaging to by plans, campaign

versus in October and results first for gross public the of most well working news, is closed before in months with In has proceeds than X of audience X financial estimated XXX,XXX in visitors expectations an that the by as deducting importantly, XXXX of more our of this with Although offering other the as and in connection offerings. approximate Jaguar campaign indicating three from visitors, general of value. increase capital net and X company offering months, the to year, only with to approximately our commercialization other perhaps corporate purposes. fees we million finding site the intends exceeded year been for the have XXXX% payable totaling less on this use target ongoing The proceeds returning Mytesi.com market approximately the Mytesi expenses the the follow-on

follow-on recent With cash to and supporting being to exciting to very going commercial, offering underpinning from we’re human from stemming the our business million development public infusion to promotional asset. continue launch Mytesi activities, of ongoing $X.X development the educational to the $X.X clinical pipeline, stemming now I'm our positioned our million this pipeline important activities. is financing, devoted and transition approximately

agents with epidermal which growth Our refer continues saving lead fluid therapy factor pipeline most in treatment to such CTD. cancer indication These is associated of can treatment termination inhibitors, may to mechanism cancer agents to is common which is patients and the as for and increase a ion to therapy. as kinase in includes this secretion it antibodies, reduction adjutant life drug targeted often co-morbidity therapy referred The action. dose be or of Diarrhea to patient I undergoing pathway, diarrhea, which the often receptor of TKI mucosa cancer a even diarrhea novel secretory effect has significant tyrosine as lead reported been leading used such from discomfort, diarrhea, side as and as gastrointestinal Crofelemer’s related sometimes extreme class Herceptin. TKIs

with dosing people in Mytesi extremely month in as also living to results care the planning HIV pivotal for by there utilizing all so the has clinical Dr. half this the indications. and importance cancer the supportive of we're analogous of for breast Genentech cancer anticipated XXXX, fact on therapy Puma indication, risk pivotal related another end comments, Roche we recognize and by therapy interim beginning the treatment as Mytesi. diarrhea. currently on out diarrhea analogous in diarrhea, care this and filing will This including discuss FDA of of on Herceptin, should which which to in progress we neratinib, using one my We supportive of next or current engaged patients XXXX patients with part which for with the a managing of cancer of investigator high in and of basically discussion protocol indication the cancer being patients Following to the ongoing, formulation program first related approved commercialized is most diarrhea are same the are mitigation, significantly potential treated for the read the rates Separately, program two or HIV successful in funded funded these Chaturvedi therapies, the is for the the with XXXX, AIDS. address related trials initiated by ran

group. Texas, Houston, A treating and Our in leaders a addition cancer guidance this hold both long-term of by Dr. to may promise DuPont, efforts Professor, prominent are therefore from University in specialist; is this the the at supported Dr. from novel Herbert in also Scientific cancer Mytesi for support Infectious area major secretory Advisory institutions. anti-diarrhea participating Napo’s treatment being thought CTD like this who other in Pablo disease Diseases, diarrhea Okhuysen treating Board, infectious of adherence members population

third-party and treatment for a loperamide to cancer recently approved not show which cancer Neratinib, care a that indicates have benefit induced supportive therapy which treat and targeted adjuvant non-clinical looking in this Neratinib drugs budesonide, therapy, to as a in approved is induced nausea diarrhea, of is chemotherapy from diarrhea. results resulting fact, vomiting, with study mitigate for TKI undergoing do works to component supportive agencies crofelemer from superior regulatory pathway diarrhea, a treatment an patients In care several precedent important has for care model. as The

second a diarrheal our pipeline voucher. on tropical our interest. diarrhea immunotherapy bowel review assessing of The other to anti-secretory diarrhea short disease, in lechlemer, prioritize supportive irritable crofelemer and includes use are is congenital a drug syndrome, of the indications to impact which for chemo idiopathic generation new also orphan development. for We've opportunity priority and designation the on are natural bowel initial even return those TKIs agent pipeline While pipeline as therefore and our disease of prioritized and radiation targeted as partner syndrome, closest activities checkpoint functional for focus, of inhibitors we traditional believe approval bowel also related such proceeds crofelemer also such a cholera agent care and based specifically have and indications, predominant disease diarrhea the focus greatest to got a inflammatory and

disease Khalifa The to marriages incidence we're the Abu access related diarrheal in diarrhea, and this status the marriages, syndrome, of to initiated City marrying meaningful for States. in addition In investigator cousins bowel more for part disease an in which orphan blood, consanguineous is short drug to region, at prevalent diarrheal much are cancer by the received where related patients these rare culture of therapy supporting study congenital disorders have therefore, for and Sheikh trial congenital we Medical we've Dhabi. United number of

with These anti-secretory NDA activity as for cases HIV. will commercial is rare Mytesi an of product, for drug. FDA any is provide because already development. the approved developers prioritized an is in and million. tropical return for are Hence, Cholera approval risk of neglected from FDA a The sold thousands vouchers first hours diarrheal X cholera and an the million indication indication product treatments in for is with with on diseases infection, possible this of approval immediate incentive FDA and the involves worst the pipeline an priority to a recorded Lilly and the reported voucher review a in According acute Eli due outbreak this illness of awarded voucher X-month for in vouchers pediatric by second cholera review that week drug now suspected deaths upon candidate Technologies party investment, $XXX over $XX began Reuters, in range drug epidemic the and for purchasers crofelemer in cases history, year million each not priority after April voucher Crofelemer granted rapid to total lechlemer just removing a worldwide is the from to and XX,XXX sold voucher reported in return dehydration kills this diseases. develop a are Siga botanical a per million, review for the investigated again final Priority indication. third called month, drug to is to since lechlemer, for suspected to $XX priority the Yemen generation cholera they disease fact new candidate. review And priority a for review cholera [indiscernible]. targeted to provide as transferable approved XXXX of XX roughly X.X Yemen, along Our application award to equation. With accelerating the sometimes, in people our the pursue efforts first XXXX. that

to crofelemer and We cholera diarrhea data for the ICDDR both have trial hospital Research, a severe on plan presented same affectionately the association we in follow and for the cholera Diarrheal International design Center for of the from for potential watery for to mechanism anti-secretory development Phase Bangladesh as action Disease of known X highly the same lechlemer ICDDR regarded support indication. conducted study in cholera patients with

from planned the pipeline, is pursuing developing infants a and our second Our our the and steps tablet potential dispersible Across which half for with globally. we of children formulation to actively goal to the clinical which be XXXX. adults involve of next work in relevant corporate progress lechlemer, IND of filing and partners, non-dilutive would support are

supply collaboration in products values Knight specified and Mytesi towards Canadian announced products Canada markets. commercialize a right and an and Latin company the our first American we right with global along Napo of in a Israel making distribution specialty of As commercialize and exclusive in marking step and an has This available this September example, related important to entered countries. products Jaguar year, is Mytesi related grants to agreement license the the pharmaceutical and into XX on Knight Therapeutics, that negotiation

Lastly, and long Napo, ensuring committed life Mytesi at Jaguar to exclusive we crofelemer, a are lechlemer. of

to my With hear now interest session. and and Thank turn as with current Pravin, emerging and class Mytesi. issued supported demonstrated listening enacted for to Mytesi growth to focus by risk have not is a for sales for more believe candidate because That's exclusivity flow of by continue our opportunity. a stable a Jaguar, the as same holding partnership more you near-term To provide our pharma time. data guidance, file first oral up, enjoying Chaturvedi we’ll generic mitigated witnessing under class and indications, for over over and which guidance, primarily Mytesi rewarding in in pathway. outside position could as the clinical of we most have our XXX the and and drug, support follow-on operational approved potentially FDA positive Napo drug Dr. company this also is We for that rights, in patents before where we proof recently And become At does cash we're already clinical pipeline administration, that, first to its approved action mechanism under in I is an an Q&A botanical about relevant product our time, approved conclude concept of exclusivity. Lechlemer Mytesi business, first within botanical test hold opportunity all extraordinary additional risk is comment. exists, global a crofelemer, we wrap of possessing continuing indication. at anti-secretory represent. indications I'll for a product Knight. we pipeline about applicability we're your you this is targeted corporate it our mitigated, the an chronic interest of same talk

Pravin Chaturvedi

action everybody. I'm about Thank of crofelemer. morning, Pravin you, I’ll talk for Good Chaturvedi. Lisa. mechanism

means any the and AIDS relief in and So crofelemer in which of class, it in by by that habits. constipating is symptomatic not with receive because the approved provide a first actually novel FDA living kind to non-infectious does diarrhea alter people is drug approved it is anti-retroviral first gut HIV therapy. the anti-diarrheal normal first It not agent that drug was a and FDA,

bowel bowel by diarrhea family referred the acute physiological physiological that but these clinical for days you indicated and approved they anti-motility risks have name from anti-motility abdominal from drugs various breakthrough which they not resulting use, and the cause, available other anti-motility of they you agents and for familiar diarrhea, less been a patients diarrhea the cause the would produce over-the-counter movements do and generic loss grandfathered and only. include [indiscernible] not cause they not of to Imodium, The drugs, constipation rebound past chronic so drug, with constipation. of electrolytes Examples The be with the diarrhea X agents to and Loperamide that reduce which These pose because the the by do which chronic actually constipation and gut address diarrhea, treatment bloating affect constipation. for Just distension are patients than and know, agents, has fluids movement, they is Furthermore, consequences are many are pain, of are the changes. are not and are diarrhea from a get cause for how ameliorating simply and motility the usage. reduction reduce they these prescription itself. motility the that's gut as in drugs opiate

CFTR unformed the hour for these that water the water constitutes of gut and electrolyte stools. passage to reduce is after watery and channel in Crofelemer of channel regulates chronic the results activated period. of technical has mechanism called intestine. there diarrhea somewhere that ensure physiological This in consecutively. the to another formation between passage the is the channel only watery liters XXX difference small anti-diarrheal that the By as intestine. ml chloride only which one mechanism of physiological fluid a an in chloride in of to chronic For diarrhea, conductance chloride of watery days of intestine, Simply electrolytes adult as is and clinical Physiologically, Even defined diarrhea moderate novel the tightly their channel stools severe at bowel has human ion between defined difference large amount chlorides have stools as for accompanying X there of watery body is well. And increase fluid less watery content gut even XXX being of the passage so more trance Lisa least and pointed and drug fibrosis is approved of the Acute that and just unable than which in either that as secretion regulator duration is ml a is for is put, XX increasing within the fluids patients content amount a unique the the Crofelemer has well risk XXX of to movements. X allow stools or diarrhea fluid called that and into as way stools modulation of the diarrhea form of and the of to reabsorbed diarrhea of regulated is generally gut. small XX adequate bowel or out and for reabsorb stools. between chloride action. in physiology and an to passage water is most bowel the Crofelemer bowel watery XX The constipation. their diarrhea in of at movement in the term movement of movements significant explanation, calcium is XX loss X a condition, watery is one or watery cystic least whereas membrane form having

will XXX stools or XXX through, you of will more you passing if that instance, then have ml ml have or watery diarrhea. for you So so

as XX act gut. as mechanism have channel will you'll XXX stools, If which less you regulator in CFTR ml a or content XX which act or passing of Crofelemer’s have fluid was hard chloride electrolyte less is through, means normalization constipation. you will going and it ensures have novel the ml the to -- of through, that

that period a on chloride to through. intensity to with down passes it the much best effects a the the in hyperactivity the shutting right and water, has amount show Depending the chloride secreted just CFTR without in ensure of being of is gut, time if its will Crofelemer patient commensurate gut, secretion chloride of effect. accompanied require fluid Crofelemer of So too regulates channel the that

So of a an to kills picture you the activity and movement envision a tank of Crofelemer, fish would aquarium I function to in tank. the like of

fluid If around in in and the it Crofelemer response the gut. chloride brings balance gut insult when nor get a a deal of movement, are secretion causing correct normal, chloride get simply and happens exactly is there to is gut the to back gut. absorption in address healthy gill the fish in moving the appropriate disease the the you And insult these if rhythmic the good neither function is disease and picture Since these notice you that that's crofelemer thing in the faster. fish in gut. their insult channel functions and gastric how ensures normal of re-absorption channel that movement nutrients. the required chloride aquarium electrolytes rhythm. of movement if in absorbed same regulates modifying, The hyperactive, appropriate the the it condition and to becomes excited, But to electrolytes agents an appropriate that channels intestinal dysrhythmia tank, the the and start itself other more to hyperactive to mucosa is an channels the and to secrete chloride associated a and

receive to stool treated addressed formation. does and patients Crofelemer HIV of crofelemer their for normalize HIV to is intestine anti-retroviral HIV they to not stool is due hardening. infection So is non-infectious a diarrhea patients, ensure the the to that by constipating being agent, chronic not therapy continue in any instance, their cause

gut does not simply the the or interactions it does actually so Crofelemer alter stools effects and channels substance. It has other of do changes have formed activity a passes not the drug are mortality functioning and opiates. appropriately, and to CFTR to calcium food or any an if So does any as patient inert medications through not chloride the the gastric unlike

medications concomitant It intolerability The the ADVENT adverse food with diarrheal the known treatment therapies significant tyrosine to therapies adjustments receive experience collateral from the compared use arm range was That of pointed trial placebo anti-retroviral watery the patients an had dose holidays for any a inhibitors people symptomatic a receiving. of X.XX led finding, our the FDA the event EGFR to that efficacy than associated relief from that Crofelemer in We inhibitors of treatment, in Phase demonstrated for reduction inhibitors. safety with regimens X which targeted much in In to their patients did thrice -- trial to proportion that daily trial, priority in receiving and damage granting Xx that or dose from that significant was cancer administered in of this or pivotal cancer. chronic very of to with diarrhea less a of drug. was called kinase such was drug any any in of is ADVENT more demonstrate review the as Crofelemer patients shown living and Lisa needed HIV weekly number diarrhea As cancer than HIV contain interactions of developing Crofelemer we treatment trial, value were demonstrated for HIV, regimens. Crofelemer not X.XXX ADVENT. to receiving that daily without the responders have due have that p to stools no we significant episodes out, in for have and medications is the designed other and with approval tyrosine intend number and diarrhea it kinase reductions a of discontinuation therapy.

will clinical in key So the in effectiveness our members, and kinase tyrosine with and drafted similar we SAB did we a cancer severity receiving Crofelemer, introducing GI opinion that study plan safety have diarrhea of products. inhibitor leaders responder analysis consultation that evaluate and protocol FDA have discussion requested in regimens. the patients, use we a to ADVENT containing We division clinical a with of

indication with diarrhea in FDA note of outcome will incorporate a an appropriate expect HIV chronic that you safety an is excellent I'll when therapy much chronic regimens. crofelemer have we cancer the protocol any evaluate crofelemer that neither related very therapy date absorbed and getting safety will drug received cancer and from has containing it will database diarrhea for leverage an Crofelemer similar now of nor opiate feedback that of diarrhea a drug neither guidance in listening. we're us tyrosine setting a Since trial. Lisa? thousands kinase thank the designing symptomatic nor We the interactions into in to turn is safety in and profile in cancer It the back an to significant inhibitor Please we patients crofelemer related patients, over in Lisa as discussion receiving antibiotic. that showed allow to for the the a well. patients relief

Lisa Conte

to At to I this up over that open monitor to please? can point, it turn we you Q&A. will [indiscernible],

Unidentified Company Representative

Sure. Thank you Pravin. very much, Lisa and

So and answer. Simon, questions please queue for

Operator

question from now We’ll take Wainwright. first Jason H.C. our Instructions] Kolbert [Operator from

Jason Kolbert

Thank you for the a very with like comprehensive update. to questions. I'd start of couple financial

fully out. count, cash diluted share what company maybe just the can Can know what's housekeeping at balance count, you share purposes, the let current the you, help is Karen, the can today? remaining Karen So what's me for

Karen Wright

total that, voting XX,XXX,XXX. and have is preferred we common shares Of XX,XXX,XXX. The stock stock common outstanding

of non-convertible and We stock as stock X,XXX,XXX preferred converted common have non-voting X,XXX,XXX.

Jason Kolbert

Okay. cash And Karen? balance, the

Karen Wright

will Our out that Q, give cash as I can't in balance the is, yet. be reported

can But net that. X of October I that tell issued -- X you were million. and not X.X we have it’s the raised million proceeds approximately our We that

Jason Kolbert

I expect Q we delayed. file? can Q that to see When was the the And

Karen Wright

fairly The Q of approved was auditors. our debt a analysis that were They complicated. review we that has final been by extinguishment doing a national did

next filed the day So that should or be within two.

Jason Kolbert

Okay.

bit those contribution any do from about Let recorded? talk adjustments? some are. basis, what of RedHill have dealing can was did going what And in should the thoughts little net look to a bit little On Mytesi of would talk we HIV I other about me little XXXX? the versus sales at the a guidance guidance, terms be but talk of the a a are go that what be how how like and it's kind gross in adjustments about revenues a you know with for you bit early you of talk we forward percent you things. Lisa, through few about And the about just can looking should

Lisa Conte

the I'll for questions the answer I here. on being Thanks can call.

more we for or guidance certainty, future in at since time, not confidence over record this now we months board giving more little getting we're XXXX in the full out I are can have So, but say had predicting commercialization for six with for the a months. track on six there a about

where look you to up think the start it’s connect a growth very and based can that get we've end about we'll dots what October growth to month because at have RedHill, your XXXX. in So, in that on you we’ll data we’ve look had quarter-on-quarter, late. we the seen at early continue

have data and and couldn't more So on of they be months but there RedHill, two we is enthusiastic growth. encouraged

is contribute, out where enough again to fully continue with I not they’ll we them I expect say guidance, I'm it in giving meaningful XXXX. would So can't that but since think

the have comment. far As a as here mix, vowed I may

XXXB, yet, because more we HIV As high in noise, large number the the awareness, resort. it's population. patient increasing utilization net, patients, to with pretty is the very last discounts increasing gross formularies, ADAP which we insurance the of we're we're get important ADAP on of the from our a prescriptions, get hit

So We has our we’re the more been – our having right forward. gross go OCR discounts, decreasing. to to has gross way that net net to think --

Karen Wright

Yes.

the we patients, additional increasing our As the docs charge ADAP the add meet discounts, needs we of meeting and needs. are and population HIV

Lisa Conte

forward? want Rob, mix that comment you to do going you on see

Robert Griffing

Sure.

expect bit Medicaid, will is we states insured of New additional because of ADAP our some as the a of programs, forward, there Medicare, the comes commercially meet bigger I mentioned been to there states the XX% you change like mix, little the government but now, What you've over a board, come said, and nice minor for and be expect right that and on we business in that here. fairly formulary mentioned, from to some do resource ones your hopefully Florida going and think are we Jason, XX% coming currently on see decision hasn't -- see were addressed stay tweaks the been weeks, about such group consistent, shift, we it it's this Lisa York additional as ADAP. but and as I nicely. that are as phone of it much in putting

Jason Kolbert

experience with a the can doctors, of business? docs, Are And bit percentage new or you those represent little what Lisa, first -- revenues in seeing how talk many time pick starting of refills to terms you up? your refill repeat prescriptions versus

Lisa Conte

pass his I'm at Bob as one to he’s because data fingertips. going well, to that over

Robert Griffing

Yeah.

So really good question.

additional prescribe. doctors seeing are We

depth prescribe the those the prescriptions, your look prescribing, of also are that's we strong and we only prescribing month growth very that one is prescribing. the depth just fact, two over quarter so in In and we're of We're but seeing time breadth breadth have prescribed prescription. in at but one not quarter metrics terms over month, are also seeing -- or of first more of that those

the sure us and familiar to it time So RX, are a we're of a being new that new and which receives a or are they're first prescribed are but it we a patient. you may the to that brand necessarily RX, Nuta Nuta a are take to encouraged, very opposed a I'm [ph] affected number IQVIA patients that of with the who in expires drug and is not isn't one out X our as which they but versus tells Nuta started be the on breaks once data representatives how brand RX prescription, that's patient new metrics is new could new new whatever fact refills, X get those piece a just where receive holiday brand have your as or counted actually paper they Jason,

what brand of twice IQVIA about actually that's see a expects the for share, XX%. chronic an to the Nuta seeing like at XX%. brand They looking ratio And Mytesi. we're average NBRX So of TRX, rate of

in which XX%, identifying their within we're are better around So are that suffer is practice continuing positive a that patients to really nice coming diarrhea. physicians with

Jason Kolbert

second can studies, start Lisa, and might talk of to can investigator we tell from I'd study talk the about about you I driven UCSF the and/or little events when coming study about those see a last, HALT-D and a and CTD the the me like And trial? little bit catalysts bit data the

Lisa Conte

Sure.

diarrhea, months. for to couple what the initiated is the of be Roche. you about related they So are of phone, just being patients have HALT mentioned that is by interim so Genentech treated enrolled, at for just to funded number everybody cancer investigator They trial else on a

of out So confident that interim be XXXX. we’re will half that results quite first read in the

treating are is so to pivotal give diarrhea, those know experience Puma in this from with the neither it important to even modifications it has population have community, the us that that neratinib related being around be don't in us going cancer in that clear, does UCSF trial make trials, a and which physician, I therapy. corner and adjuvant the but trials to if of patient be of the let’s study is enrolling, that potentially awareness crofelemer patient Neither in those that. going more cancer indication in for community. give will the in their There is will they some protocol, treatment even just The yet. and first funded by the started we're So study just be

the So targeting the is the pivotal now. FDA we're literally that with of trial discussion the basis

for have require two, filed next funding We've month Actually trial Within in point a at that. we'll pulling that or will non-dilutive already that this from starting the discussion. source.

working know, the you pull year. on not start of the off the we have be sufficient for did activities. as one So, trial. corporate us to before funding to partnering been That's able We first cancer end

or of want to to the time of you because useful to that. and to pivotal extent greatest funding we'll once particularly, trial, -- a FDA realistic the So do place, KOLs, program, we a necessary able enrollment a spot about front you in to definition. agreement, start are with we of to that want clinical practical to we're any moving not it's have that have Put here, get the want met be moving endpoint be that success probability but criteria have in trial, that we

clinical comes when trials. get to start we're So but down the to pipeline so. out do by diabetes, we’re related immediately ground cancer moving when way, to out early of one, any the doing the hitting regulatory of go only we as the have ready funding one the getting much that risk the not way, implementations those trials clinical we're into in, something so And

Operator

next Jon take question now from Glaser JMP our Capital. [Operator Instructions] from We'll

Jon Glaser

question, of the can trends relative same just about trajectory us tell A And versus the before? sales time as the October in from you or then force referred were of might your you be if months to to last sort X the in coming to to own? month now, briefly, X with from what you regard RedHill’s months your percentage to of RedHill, guestimate sales the

Lisa Conte

question So a first were the didn't I low I'm first for hear sorry. the quite little bit. and question. just you

Jon Glaser

sorry. I'm

are you you You’ve that the October. trends on October confirm in mentioned trajectory month basically the in Can of months briefly as before? the same saw the

Lisa Conte

can I definitely out you. and that we the you confirm plot numbers that can gave

or early. expectations growth So, out want with the RedHill. And are growth yeah, highly October, as any we're It's see. continuing there don't to in as we to I encouraged RedHill, numbers the put far for

months for As of I said, them. two have we data only

they're, part in So different part, long discipline. a And the sales we projections most in that know and our is force. our to for how us medical it own forecasting because, of from feel took confident

dealing infectious the disease with, to part, the prescribing docs the most for decile, high with we're anti-retroviral diarrheal high docs. So

diarrhea about X, their talking X floodgates to talking physician X, patient open. their in can then me and about the you start So start patients say, details patient HIV and population heard is do it be before think and challenge you've get is diarrhea I population our the

right now, with months where population HIV. experience we office of is a there, meaningful So there a in two GI have them

to label but no patients. the their on is means of majority that it's So them, by target

to tell prescriptions went can in this able forecasting before primary we and have they two -- So we about reason for be what the do. it get on may confidence projecting to you, it’s taking They happen And that's to what to back the grew. But have months, up. learn I point. holding there, they

Operator

our next from Capital. take Ed Aegis from now We’ll question Jeffrey [ph]

Unidentified Analyst

understanding just but I have to wanted so this, forward. clarify, of just your going you think an I I touched funding on

going lot are partnerships, You all on, have funding going activities hand, your cash your how forward. a on

Lisa Conte

from the would expect for partnering. activities fund clinical we trials, pipeline, Our going into from non-dilutive sources corporate to clinical

that's in, Canada as we've Israel of was. our about come that an example, Knight meaningful and So saw we the is how and in marketplace said, global that partnership, X% to

of partnerships the to get the to devoted portion ready we clinical we the to raised in global is in sufficient of small trials. as we we We October, a get funds to corporate some pursue just max, are populations non-dilutive partnership, being expect these that take to have the this dollars pursuing, financing the million that pipeline that $X.X in clinical would larger about for So of trial.

have that's now. So We're do now, as out as we activities that, taken risk that and further a I KOLs, mitigates much discussed, the you as so already getting planning getting activities, regulatory all protocol, possible. as the the preparatory for anyway, to activities way of approved we're regulatory risk have time even the that with done drug those and

goal the indication, For the goal to the foundation. is -- financial for right have a now chronic selling Mytesi solid Mytesi,

breakeven and position that stream. What do same and to allow is we’ve receiving is of within credit ourselves we a equity now, We're funding because project ourselves opportunity we get the an for selling means. our There's get to to that confident going way there the we equity opportunities. historically. can that planned. we're still are plan at None So always have looking not revenue sales royalty we do revenue and currently have purpose. if Mytesi funded sure We to planned of feel us is always current to is and line from

Operator

telephone this are or It Instructions] remarks. turn would time. appears host for further any to additional no back questions I our [Operator over to on like the closing the there at conference

Lisa Conte

work get here. time to Thank it we're you all this morning. going for and appreciate We the to back

mantra Our Mytesi. here is Mytesi, Mytesi,

and story march. So appreciate company. that's to going we're your the interest where I the in

Operator

this and for call. you participation. your Thank today's Ladies gentlemen, concludes

now disconnect. may You

Jaguar Health (JAGX) 15 Nov 182018 Q3 Earnings call transcript